Annexin A3 (ANXA3) is a member of the annexin superfamily, calcium-dependent phospholipid-binding proteins implicated in diverse cellular processes, including membrane trafficking, signal transduction, and inflammation regulation. ANXA3 is characterized by a conserved C-terminal core domain that binds phospholipids in a calcium-dependent manner and a unique N-terminal region that mediates interactions with other proteins. It is expressed in various tissues, with notable roles in immune cells, epithelial cells, and certain cancer types.
ANXA3 antibodies are essential tools for studying the protein's expression, localization, and function. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect ANXA3 in biological samples. Research has linked ANXA3 to pathological conditions, particularly cancer. Overexpression of ANXA3 has been observed in multiple malignancies, including breast, prostate, and hepatocellular carcinomas, where it is associated with chemoresistance, metastasis, and poor prognosis. Its role in cancer progression involves modulating apoptosis, cell adhesion, and extracellular vesicle formation.
In non-cancer contexts, ANXA3 is implicated in inflammatory responses, wound healing, and cellular stress responses. Antibodies targeting ANXA3 help elucidate its dual roles in homeostasis and disease, offering insights into its potential as a diagnostic biomarker or therapeutic target. However, its tissue-specific expression patterns and functional complexity necessitate careful validation of antibody specificity to avoid cross-reactivity with other annexins. Recent studies also explore ANXA3's involvement in exosome-mediated communication and immune evasion mechanisms, highlighting its multifaceted biological significance.